TY - JOUR
T1 - Prevention of colonic neoplasia with polyethylene glycol
T2 - A short term randomized placebo-controlled double-blinded trial
AU - Wali, Ramesh K.
AU - Bianchi, Laura
AU - Kupfer, Sonia
AU - De La Cruz, Mart
AU - Jovanovic, Borko
AU - Weber, Christopher
AU - Goldberg, Michael J.
AU - Rodriguez, L. M.
AU - Bergan, Raymond
AU - Rubin, David
AU - Tull, Mary Beth
AU - Richmond, Ellen
AU - Parker, Beth
AU - Khan, Seema
AU - Roy, Hemant K.
N1 - Funding Information:
This study was supported by funding from the United States National Institutes of Health N01-CN-35157. ClinicalTrials.gov number is NCT00828984, www.nih.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
This is an open access article, free of all copyright, and May be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
PY - 2018/4
Y1 - 2018/4
N2 - Chemoprevention represents an attractive modality against colorectal cancer (CRC) although widespread clinical implementation of promising agents (e.g. aspirin/NSAIDS) have been stymied by both suboptimal efficacy and concerns over toxicity. This highlights the need for better agents. Several groups, including our own, have reported that the over-the-counter laxative polyethylene glycol (PEG) has remarkable efficacy in rodent models of colon carcinogenesis. In this study, we undertook the first randomized human trial to address the role of PEG in prevention of human colonic neoplasia. This was a double-blind, placebo-controlled, three-arm trial where eligible subjects were randomized to 8g PEG-3350 (n = 27) or 17g PEG-3350 (n = 24), or placebo (n = 24; maltodextrin) orally for a duration of six months. Our initial primary endpoint was rectal aberrant crypt foci (ACF) but this was changed during protocol period to rectal mucosal epidermal growth factor receptor (EGFR). Of the 87 patients randomized, 48 completed study primary endpoints and rectal EGFR unchanged PEG treatment. Rectal ACF had a trend suggesting potentially reduction with PEG treatment (pre-post change 1.7 in placebo versus -0.3 in PEG 8+ 17g doses, p = 0.108). Other endpoints (proliferation, apoptosis, expression of SNAIL and E-cadherin), previously noted to be modulated in rodent models, appeared unchanged with PEG treatment in this clinical trial. We conclude that PEG was generally well tolerated with the trial failing to meet primary efficacy endpoints. However, rectal ACFs demonstrated a trend (albeit statistically insignificant) for suppression with PEG. Moreover, all molecular assays including EGFR were unaltered with PEG underscoring issues with lack of translatability of biomarkers from preclinical to clinical trials. This data May provide the impetus for future clinical trials on PEG using more robust biomarkers of chemoprevention.
AB - Chemoprevention represents an attractive modality against colorectal cancer (CRC) although widespread clinical implementation of promising agents (e.g. aspirin/NSAIDS) have been stymied by both suboptimal efficacy and concerns over toxicity. This highlights the need for better agents. Several groups, including our own, have reported that the over-the-counter laxative polyethylene glycol (PEG) has remarkable efficacy in rodent models of colon carcinogenesis. In this study, we undertook the first randomized human trial to address the role of PEG in prevention of human colonic neoplasia. This was a double-blind, placebo-controlled, three-arm trial where eligible subjects were randomized to 8g PEG-3350 (n = 27) or 17g PEG-3350 (n = 24), or placebo (n = 24; maltodextrin) orally for a duration of six months. Our initial primary endpoint was rectal aberrant crypt foci (ACF) but this was changed during protocol period to rectal mucosal epidermal growth factor receptor (EGFR). Of the 87 patients randomized, 48 completed study primary endpoints and rectal EGFR unchanged PEG treatment. Rectal ACF had a trend suggesting potentially reduction with PEG treatment (pre-post change 1.7 in placebo versus -0.3 in PEG 8+ 17g doses, p = 0.108). Other endpoints (proliferation, apoptosis, expression of SNAIL and E-cadherin), previously noted to be modulated in rodent models, appeared unchanged with PEG treatment in this clinical trial. We conclude that PEG was generally well tolerated with the trial failing to meet primary efficacy endpoints. However, rectal ACFs demonstrated a trend (albeit statistically insignificant) for suppression with PEG. Moreover, all molecular assays including EGFR were unaltered with PEG underscoring issues with lack of translatability of biomarkers from preclinical to clinical trials. This data May provide the impetus for future clinical trials on PEG using more robust biomarkers of chemoprevention.
UR - http://www.scopus.com/inward/record.url?scp=85045014607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045014607&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0193544
DO - 10.1371/journal.pone.0193544
M3 - Article
C2 - 29617381
AN - SCOPUS:85045014607
SN - 1932-6203
VL - 13
JO - PLoS One
JF - PLoS One
IS - 4
M1 - e0193544
ER -